Uorane_tuga@Uorane_tuga

1Mês

What made you buy this specific one tho?🧐

Gosto••Resposta

JH@DiosmioSanto

1Mês

@Uorane_tuga

- Reasonable P/E ~19
- EPS rising + buybacks = negative dilution
- Revenue climbing, with upside from oncology pipeline (colorectal, kidney, solid tumors)
- US-based → less regulation hassle
Others may fit, but this one ticks all my boxes.

Gosto•

👍

11

•Resposta